Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDG1021 in Relapsed/Persistent Hematologic Malignancies Post-HSCT
NCT04464889Phase 1Withdrawn
- Sponsor
- Medigene AG
- Start
- Jul 2020
- Primary completion
- Jul 2023
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of MDG1021 in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and 5 more, sponsored by Medigene AG. Primary endpoints: Safety and tolerability of HA-1H TCR transduced T cells: incidence and severity of adverse events at 28 days, Maximum Tolerated Dose at 28 days and 1 more. Planned start Jul 2020; status: withdrawn.
02
Drugs
MDG1021
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)myeloproliferative neoplasms (MPN)chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT04464889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04464889.